Stay updated on Obicetrapib + Ezetimibe Adjunct in HIS Therapy Clinical Trial
Sign up to get notified when there's something new on the Obicetrapib + Ezetimibe Adjunct in HIS Therapy Clinical Trial page.

Latest updates to the Obicetrapib + Ezetimibe Adjunct in HIS Therapy Clinical Trial page
- Check6 days agoChange DetectedNew revision v3.3.2 appears in the Record History, superseding v3.3.1.SummaryDifference0.1%

- Check13 days agoChange DetectedRevision: v3.3.1 was added to the page history and Revision: v3.2.0 was removed.SummaryDifference0.1%

- Check20 days agoChange DetectedThe government funding notice banner was removed from the page, removing the lapse-in-funding message previously shown. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check34 days agoChange DetectedThe Record History shows updates to the ROSE2 trial across multiple versions, including recruitment and study status changes in 2022 and a 2024 update that adds/adjusts Study Status, Outcome Measures, and related sections, along with updates to Contacts/Locations and Study Design.SummaryDifference0.1%

- Check63 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference13%

- Check70 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.3%

Stay in the know with updates to Obicetrapib + Ezetimibe Adjunct in HIS Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Obicetrapib + Ezetimibe Adjunct in HIS Therapy Clinical Trial page.